Promescent OTC For Premature Ejaculation Builds On Physician Strategy
This article was originally published in The Tan Sheet
Executive Summary
Sales of Promescent, an OTC external analgesic indicated for premature ejaculation available for 18 months online, jumped in the past year with distribution by urologists and other doctors. “The PE space is wide open. That is nothing short of amazing to me,” says Absorption Pharmaceuticals CEO Jeff Abraham.
You may also be interested in...
With OTC Lidocaine, Salonpas Takes Path Of Less Resistance To Market
Hisamitsu America looked to the OTC lidocaine market after deciding it would have to wait too long for an ANDA approval for an Rx generic. "We really saw the opportunity in the OTC space with a 4% OTC patch," says President and CEO John Incledon.
With OTC Lidocaine, Salonpas Takes Path Of Less Resistance To Market
Hisamitsu America looked to the OTC lidocaine market after deciding it would have to wait too long for an ANDA approval for an Rx generic. "We really saw the opportunity in the OTC space with a 4% OTC patch," says President and CEO John Incledon.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”